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Abstract Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) is a key glycolytic enzyme regulated by many diverse 
mechanisms. In this study we present evidence that GAPDH 
activity is stimulated in the presence of oxyhemoglobin (2.3-fold, 
P< 0.005). No stimulation was seen by myoglobin, and only 
slight stimulation (1.2-fold, not significant) by methemoglobin 
was observed. Such stimulation may have physiological sig-
nificance as 1,3-bis-phosphoglycerate, the product of GAPDH, 
isomerises to 2,3-bis-phosphoglycerate, an allosteric effector that 
decreases the oxygen affinity of hemoglobin, thus providing a 
feedback loop. The results suggest that when assaying GAPDH 
activity in biological samples, hemoglobin content should be 
taken into account. 
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1. Introduction 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
EC1.2.1.12) is a key enzyme in glycolysis, catalysing the con-
version of glyceraldehyde-3-phosphate to 1,3-bis-phospho-
glycerate. Previous work has indicated that this enzyme may 
be subject to regulation by multiple mechanisms [1-12]. There 
is evidence to suggest that GAPDH is inhibited by a nitric 
oxide dependent ADP ribosylation [1-3] and recent work sug-
gests that this method of regulation may in fact proceed by 
the covalent linking of an NAD+ molecule to the enzyme 
following nitrosylation of a cysteine residue [2]. Oxygen free 
radicals have been observed to enhance this inhibition in cul-
tured neurones [4]. In erythrocytes, an increased production of 
free radicals may cause GAPDH to traverse the plasma mem-
brane, leading to up-regulation of erythrocyte glycolysis in 
times of oxidative stress [5]. It is reported that GAPDH is 
inhibited by interaction with erythrocyte membranes [6] and 
tubulin complexes [7], and activated by interaction with oc-
amino acids, ATP and dithiothreitol [8], although other evi-
dence suggests dithiothreitol may inhibit the enzyme [9]. 
GAPDH also interacts with the cytosolic domain of the Alz-
heimer's ß-amyloid protein [10], calmodulin [11], and its 
neighbouring glycolytic enzyme 3-phosphoglycerate phospho-
kinase (PGK) [12], although these interactions do not appear 
to affect the enzyme's activity, and may serve to sequester it 
away from other cellular components. 
In the current study a routine series of GAPDH activity 
assays in liver cytosolic fractions gave a wide range of values. 
As tissue samples contained differing amounts of blood, and 
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GAPDH activities were expressed per mg protein, it was de-
cided to assay for hemoglobin and correct for its presence. 
However, upon examining GAPDH activity and hemoglobin 
content data, a distinct correlation was noticed between them, 
and it was decided to investigate this further using purified 
enzyme and hemoglobin. 
2. Materials and methods 
All enzymes and biochemicals were from Sigma, Poole, Dorset, 
UK. Mice of the C57/CBA strain were maintained and killed under 
recognised procedures of the Animals (Scientific Procedures) act 1986. 
Following sacrifice, liver was removed and frozen at —70°C until use. 
After thawing, tissue (100 mg) was homogenised (glass:glass, 0.1 mm 
clearance) in 3 ml ice cold assay buffer (110 mM triethanolamine-
hydrochloride, pH 7.6 with Tris at 30°C), and centrifuged at 60000 
rpm (152500Xg) in a fixed angle rotor. The supernatant was retained 
for enzyme assays and pellet discarded. 
GAPDH activity was measured by following the backward reaction 
converting NADH to NAD+, at 340 nm [13] in a Uvikon 940 spec-
trophotometer. The assay buffer contained triethanolamine-hydro-
chloride (110 mM), ß-NADH (200 μΜ), EDTA (0.9 mM) and MgS04 
(1.7 mM), pH 7.6 at 30°C. 3-phosphoglyceric acid (6 mM) and ATP 
(1.1 mM) were added as substrates for the auxiliary enzyme PGK (15 
U/ml). Cytosolic fraction samples (10 μΐ) were added neat, and for the 
in vitro analysis GAPDH of approximately the same final activity 
(100 nmol/min/ml) was added (10 μΐ). Hemoglobin, myoglobin, or 
methemoglobin dissolved in water were added to give final concen-
trations of 0.01-0.1 mg/ml. Hemoglobin was purchased in the Ao 
ferrous form, essentially free of methemoglobin. Scanning wavelength 
spectrophotometric analysis was used to confirm this (result not 
shown). To check that any effect of hemoglobin was not an artefact 
of the assay method, GAPDH activity was also measured in the for-
ward direction, with glyceraldehyde-3-phosphate, ß-NAD+ and pyro-
phosphate as substrates, with arsenate present to inhibit the back 
reaction [14]. 
The hemoglobin content of samples was assayed by following the 
catalytic action of hemoglobin on the oxidation of tetramethyl benzi-
dine by hydrogen peroxide at 600 nm, using Sigma assay kit #527 
[15]. Protein was measured by the Lo wry method [16] with bovine 
serum albumin as standard. For liver homogenates, data were ex-
pressed per mg of non-hemoglobin protein, following corrections for 
amounts of hemoglobin contamination. Statistical analysis was by the 
Student's i-test. 
3. Results 
Fig. 1 shows mouse liver cytosolic fraction GAPDH activity 
(expressed per mg non-hemoglobin protein) as a function of 
hemoglobin concentration. The total protein content of sam-
ples was in the range 28.6 to 41.0 mg/ml, and hemoglobin 
content was in the range 0.64 to 2.87 mg/ml. Thus, hemoglo-
bin made up no more than 10% of total protein, and the 
shape of the curve in Fig. 1 is not altered if activities are 
expressed per mg total protein (not shown). 
Greater GAPDH activities are associated with greater he-
moglobin concentrations, suggesting that hemoglobin may be 
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Fig. 1. GAPDH activity and hemoglobin concentration in mouse 
liver cytosolic fractions. Data were obtained as in Section 2. Activ-
ity values are means ± S.E.M. of three determinations. N.b. protein 
concentrations are corrected for hemoglobin content, so data are ex-
pressed per mg non-hemoglobin protein. 
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Fig. 2. Effect of added globin proteins on the activity of GAPDH 
(black bars: hemoglobin, white bars: myoglobin, shaded bars: 
methemoglobin). Values are expressed as percentages of control (no 
globin) values, and are means ± S.E.M. of 6 independent experi-
ments. An asterisk indicates P < 0.005 relative to controls. 
activating GAPDH. Because GAPDH is present in large 
quantities in erythrocytes, the observation that those samples 
with greater amounts of blood contamination (indicated by 
more hemoglobin) have greater GAPDH activity is not sur-
prising. To investigate whether the relationship between 
GAPDH activity and hemoglobin concentration was of a 
cause and effect nature, a series of in vitro assays were per-
formed using purified enzyme and hemoglobin. 
Fig. 2 shows the effect of globin proteins on the activity of 
purified rabbit muscle GAPDH. The graph clearly shows that 
oxyhemoglobin stimulates GAPDH (in solution, hemoglobin 
rapidly binds oxygen to become oxyhemoglobin; the oxidative 
state of hemoglobin was checked by scanning wavelength 
spectrophotometry, monitoring peaks at 420, 540 and 580 
nm). Fig. 1 only reports activities at 10 and 100 μg/ml globin, 
as stimulation by hemoglobin reached a plateau at around 10 
μg/ml (not shown). Myoglobin had no significant effect on 
GAPDH activity, suggesting that the stimulation is not just 
a protein agglutination effect. Methemoglobin showed slight 
stimulation, though not as much as oxyhemoglobin. There 
was no measurable rate in the presence of hemoglobin and 
absence of enzyme (not shown), indicating that hemoglobin 
does not catalyse the reaction itself. The effect of deoxyhemo-
globin was tested by using dithionite to deplete oxygen in the 
assay mixture, but dithionite alone decreased the GAPDH 
activity, presumably through an effect on the thiol groups of 
GAPDH, or by re-reducing NAD+ made by the reaction (re-
sult not shown). As methemoglobin does not bind oxygen, we 
assume that it behaves similarly to deoxyhemoglobin. Hemo-
globin that had been denatured by boiling gave similar results 
to methemoglobin (not shown). 
GAPDH activity was also measured in the forward direc-
tion, to ensure that any stimulation by hemoglobin was not 
due to interaction with the auxiliary enzyme PGK, or a 
strengthening of the reported interaction between GAPDH 
and PGK [12]. Such experiments gave identical results to 
those in Fig. 2 (not shown), indicating that hemoglobin inter-
acts directly with GAPDH, not via PGK. 
4. Discussion 
Overall, the results presented here suggest that oxyhemo-
globin interacts directly with GAPDH to stimulate it. This is 
the first reported stimulation of GAPDH by another protein. 
Interactions with low molecular mass compounds both inhibit 
[1-3,9] and stimulate [8] the enzyme, and other proteins either 
inhibit it [7] or have no effect [10-12]. 
The observation that hemoglobin concentration and 
GAPDH activity correlate positively is in contrast to the find-
ings of a study in sickle cell anaemia patients [17]. The authors 
report that sickle cell patients fell into two sub-groups, and 
that the group with the highest hemoglobin count had the 
lowest erythrocyte GAPDH activity. However, the abnormal 
nature of sickle cell hemoglobin, or other factors in the path-
ology of sickle cell disease may account for this apparent 
discrepancy. 
Stimulation of GAPDH by oxyhemoglobin may be ration-
alised by examining the scheme depicted in Fig. 3. The prod-
uct of GAPDH, 1,3-diphospho-glycerate, can isomerise to 2,3-
diphospho-glycerate (2,3-DPG) via the enzyme diphospho-
glycerate mutase (DPGM). 2,3-DPG is a well established al-
losteric effector of hemoglobin [18], decreasing its affinity for 
oxygen by favouring the deoxy form when bound. The oxygen 
carrying capacity of hemoglobin and the rate of erythrocyte 
glycolysis are closely linked, as the latter will control the 
availability of 2,3-DPG [19]. Thus we propose a simple feed-
back loop mechanism whereby oxyhemoglobin may modulate 
glycolysis to affect its own oxygen carrying capacity. 
At first sight this would appear to be in contrast to the 
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Fig. 3. Schematic representation of a possible physiological function 
of GAPDH stimulation by oxyhemoglobin in erythrocytes. 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase, PGK: 3-phos-
phoglycerate phosphokinase, DPGM: diphosphoglycerate mutase, 
Hb: deoxyhemoglobin, HbOg: oxyhemoglobin. 
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results of Oski et a l , who report that deoxyhemoglobin stim-
ulates the synthesis of 2,3-DPG in an in vitro glycolytic sys-
tem [20]. However, this is due to the binding of 2,3-DPG by 
deoxyhemoglobin, removing product inhibition of DPGM. 
The authors also report stimulation of glycolysis by foetal 
hemoglobin, which has a much lower affinity for 2,3-DPG. 
This result may be explained by the current proposed mech-
anism - action at the site of GAPDH and not DPGM, 
although the use of carboxyhemoglobin in these experiments, 
not oxyhemoglobin, makes their interpretation difficult. 
The current results are also interesting with respect to the 
effects of nitric oxide (NO) on GAPDH activity. NO binds 
hemoglobin, converting it to methemoglobin (Fe2+ -> Fe3+) 
[21]. We have shown that methemoglobin only slightly stim-
ulates GAPDH, so some of the observed NO induced inhib-
ition of GAPDH [1^1] may in fact be due to removal of 
stimulatory oxyhemoglobin rather than direct inhibition. Dif-
ferent amounts of blood contamination in tissue samples may 
account for the conflicting results of these experiments [1,2]. 
A characteristic of Alzheimer's disease is senile plaques 
abundant in abnormally processed proteins such as the ß-A4 
amyloid peptide [22] and hemoglobin fragments [23]. GAPDH 
binds to the C-terminal domain of the amyloid precursor pro-
tein (APP) [10], and antibodies raised to ß-amyloid cross-react 
with oxyhemoglobin [24]. These observations suggest that 
GAPDH may bind to oxyhemoglobin, agreeing with the re-
sults of the current investigation. 
It was recently reported that GAPDH may be involved in 
age induced neuronal apoptosis [25]. The possible localisation 
of GAPDH at Alzheimer's plaques by ß-A4 amyloid or he-
moglobin fragments, and the subsequent stimulation of 
GAPDH by oxyhemoglobin, may lead to an increased rate 
of apoptosis in neurones surrounding the plaques, possibly 
accounting for some of the pathological symptoms of the 
disease. 
As a final cautionary note, we would advise those analysing 
GAPDH activities in tissue samples to also assay for hemo-
globin and correct for its presence, or possibly add a saturat-
ing amount to all samples to ensure that different levels of 
blood contamination do not affect results. 
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